Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.

Imbruvica faces challenges on multiple fronts.

Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.

Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.

Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?

With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.